NNI-362

NNI-362 has been studied in 2 papers since 2021: 1 trial in people, 1 in animals. The newest paper, Aug 7, 2025: “First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population”.

Intervention

2 papers study it5 findingsUpdated

See all 2 papers on NNI-362

At a glance

The findings reach people, from one lab or study. 2 independent labs in 1 country; 1 trial, none about aging.

“NNI-362, at the two highest multiple doses, significantly reduced plasma p-tau181 levels compared to pretreatment levels (P < 0.0012 to P < 0.0009)”
First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged populationAlzheimer's research & therapy2025doi:10.1186/s13195-025-01837-0

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 2 independent labs in 1 country
  • 1 trial, none about aging
  • Funders: National Institute on Aging and 1 more
  • 5 of 5 findings with company ties
  • 1 of 1 trial sponsored by its developers
  • Human trial1
  • Animals1

Studies in people

1 study gave NNI-362 to people and measured what changed.

What changedDesignPeopleSource

down: Decreases P-TAU181

Randomized trialsingle dose or 10-day multiple dose56 people50–72 years of ageHealthy aged subjectsAlzheimer's research & therapy, Aug 7, 2025

What did studies of NNI-362 find?

4

Studies of NNI-362 measured 4 outcomes, among them P-TAU181, cognitive function and neurogenesis.

P-TAU181

downin humans1

1 study
  1. NNI-362 decreases P-TAU181 in humans.

    Human trialplasmasingle dose or 10-day multiple dose

  2. NNI-362 decreases P-TAU181 in humans (healthy, cognitively-unimpaired) (P < 0.0012 to P < 0.0009).

    Human trialhealthy, cognitively-unimpairedoral

More on P-TAU181

Cognitive function

upin mice1

1 study
  1. NNI-362 improves cognitive function in mice (aged mice and Down syndrome-modeled mice).

    Animalsaged mice and Down syndrome-modeled mice

Neurogenesis

upin human cells1

1 study
  1. NNI-362 increases neurogenesis in human cells.

    Cellsneural progenitor cell

RPS6KB1

upin human cells1

1 study
  1. NNI-362 activates RPS6KB1 in human cells.

    Cellsneural progenitor cell

More on RPS6KB1

Trial sponsors

Latest